West Pharmaceutical Services Announces Upcoming Investor Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy WST?
Source: Newsfilter
- Investor Conference Schedule: West Pharmaceutical Services will participate in the Barclays Global Healthcare Conference on March 10, 2026, and the KBCM Healthcare Forum on March 18, 2026, showcasing its innovative solutions in injectable drug administration, which is expected to attract investor interest and enhance the company's market image.
- Webcast Availability: The company will provide live webcasts of these events on its website's Investors section, with replays available for approximately 90 days, a move that not only enhances transparency but also offers convenience for investors who cannot attend live, thereby improving investor relations.
- Company Background: West Pharmaceutical Services is a leading provider of injectable solutions, generating $3.07 billion in net sales for fiscal year 2025, demonstrating its strong market position and growth potential, which attracts trust and collaboration from numerous drug developers.
- Global Operational Scale: With over 10,000 employees across 50 locations, including 25 manufacturing facilities, the company delivers over 41 billion components and devices annually, ensuring efficient production capabilities and reliable support for its customers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WST
Wall Street analysts forecast WST stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 254.340
Low
285.00
Averages
348.70
High
375.00
Current: 254.340
Low
285.00
Averages
348.70
High
375.00
About WST
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
West Pharmaceutical Services Announces Upcoming Investor Conferences
- Investor Conference Schedule: West Pharmaceutical Services will present at upcoming investor conferences, with live webcasts accessible via the Investors section of the company's website, and replays available for approximately 90 days post-event, aimed at enhancing investor engagement and transparency.
- Company Overview: West Pharmaceutical Services is a global leader in innovative injectable drug administration solutions, dedicated to providing high-quality injectable solutions to drug developers, ensuring the safe and effective delivery of life-saving medicines, highlighting its critical role in the industry.
- Financial Performance: In fiscal year 2025, West generated $3.07 billion in net sales, indicating strong market performance and sustained growth potential, further solidifying its position as an industry leader.
- Global Operational Scale: The company employs over 10,000 team members across 50 sites, including 25 manufacturing facilities, delivering over 41 billion components and devices annually, showcasing its robust production capacity and market influence.
See More
West Pharmaceutical Services Announces Upcoming Investor Conferences
- Investor Conference Schedule: West Pharmaceutical Services will participate in the Barclays Global Healthcare Conference on March 10, 2026, and the KBCM Healthcare Forum on March 18, 2026, showcasing its innovative solutions in injectable drug administration, which is expected to attract investor interest and enhance the company's market image.
- Webcast Availability: The company will provide live webcasts of these events on its website's Investors section, with replays available for approximately 90 days, a move that not only enhances transparency but also offers convenience for investors who cannot attend live, thereby improving investor relations.
- Company Background: West Pharmaceutical Services is a leading provider of injectable solutions, generating $3.07 billion in net sales for fiscal year 2025, demonstrating its strong market position and growth potential, which attracts trust and collaboration from numerous drug developers.
- Global Operational Scale: With over 10,000 employees across 50 locations, including 25 manufacturing facilities, the company delivers over 41 billion components and devices annually, ensuring efficient production capabilities and reliable support for its customers.
See More
Eli Lilly's Dominance in Obesity Drug Market Reinforced
- Clinical Trial Comparison: Eli Lilly's Zepbound demonstrated superior efficacy in a head-to-head trial, with participants losing an average of 25.5% of their body weight compared to Novo Nordisk's CagriSema at 23%, reinforcing Lilly's leadership in obesity drug effectiveness and solidifying its market position.
- New Device Launch: Lilly introduced a new Zepbound injection device in the U.S. that provides a month's supply, enhancing patient convenience; while the immediate financial impact may be limited, it showcases Lilly's supply chain advantages and commitment to patient care.
- Significant Market Reaction: Following disappointing trial results, Novo Nordisk's shares fell over 15%, while Lilly's stock rose more than 4%, reflecting investor confidence in Lilly's growth potential and widening the gap between the two companies in the market.
- Future Development Potential: Lilly is advancing multiple next-generation obesity treatments, including retatrutide and eloralintide, targeting appetite-related hormones, with analysts noting that Lilly's competitive edge is expanding, positioning the company for further market leadership in the obesity drug sector.
See More
West Pharmaceutical Services Authorizes $1B Share Repurchase Program
- Share Repurchase Program: West Pharmaceutical Services' board has authorized a share repurchase program of up to $1 billion, indicating strong confidence in the company's value and aiming to enhance earnings per share through this initiative.
- Completion of Previous Buyback: The company has fully executed its prior buyback program, which expired on December 31, demonstrating a proactive approach to capital management and a commitment to shareholder returns.
- Optimistic Performance Outlook: West Pharmaceutical targets organic revenue growth of 5% to 7% for 2026, primarily driven by accelerating demand for high-value products (HVP), reflecting strong market demand for its offerings.
- Exceeding Market Expectations: The company reported fourth-quarter results for 2025 that surpassed market expectations, further boosting investor confidence in its future growth potential and likely attracting increased investor interest.
See More
West Pharmaceutical Declares Quarterly Dividend and Share Repurchase Program
- Quarterly Dividend Declaration: On February 16, 2026, West Pharmaceutical's Board declared a quarterly dividend of $0.22 per share, payable on May 6, 2026, to shareholders of record on April 29, 2026, reflecting the company's ongoing profitability and commitment to shareholder returns.
- Share Repurchase Program Initiation: The company authorized a new share repurchase program on February 17, 2026, allowing for the repurchase of up to $1 billion in common stock, aimed at enhancing shareholder value and boosting market confidence through flexible adjustments based on market conditions and stock price fluctuations.
- Repurchase Flexibility: This repurchase program has no expiration date, allowing the company to suspend or terminate it at any time based on market conditions, demonstrating its flexibility in capital management and ability to respond to market volatility.
- Successful Historical Repurchase: West Pharmaceutical fully utilized its previous repurchase program before its expiration on December 31, 2025, indicating a proactive approach to capital returns and effective shareholder value management.
See More
WEST PHARMACEUTICAL SERVICES INC: UBS LOWERS TARGET PRICE FROM $355 TO $340
Company Overview: West Pharmaceutical Services, Inc. is a leading provider of pharmaceutical packaging and delivery solutions.
Stock Price Adjustment: The company has cut its target stock price from $355 to $340.
See More
West Pharmaceutical Services Announces Upcoming Investor Conferences
- Investor Conference Schedule: West Pharmaceutical Services will present at upcoming investor conferences, with live webcasts accessible via the Investors section of the company's website, and replays available for approximately 90 days post-event, aimed at enhancing investor engagement and transparency.
- Company Overview: West Pharmaceutical Services is a global leader in innovative injectable drug administration solutions, dedicated to providing high-quality injectable solutions to drug developers, ensuring the safe and effective delivery of life-saving medicines, highlighting its critical role in the industry.
- Financial Performance: In fiscal year 2025, West generated $3.07 billion in net sales, indicating strong market performance and sustained growth potential, further solidifying its position as an industry leader.
- Global Operational Scale: The company employs over 10,000 team members across 50 sites, including 25 manufacturing facilities, delivering over 41 billion components and devices annually, showcasing its robust production capacity and market influence.
See More
West Pharmaceutical Services Announces Upcoming Investor Conferences
- Investor Conference Schedule: West Pharmaceutical Services will participate in the Barclays Global Healthcare Conference on March 10, 2026, and the KBCM Healthcare Forum on March 18, 2026, showcasing its innovative solutions in injectable drug administration, which is expected to attract investor interest and enhance the company's market image.
- Webcast Availability: The company will provide live webcasts of these events on its website's Investors section, with replays available for approximately 90 days, a move that not only enhances transparency but also offers convenience for investors who cannot attend live, thereby improving investor relations.
- Company Background: West Pharmaceutical Services is a leading provider of injectable solutions, generating $3.07 billion in net sales for fiscal year 2025, demonstrating its strong market position and growth potential, which attracts trust and collaboration from numerous drug developers.
- Global Operational Scale: With over 10,000 employees across 50 locations, including 25 manufacturing facilities, the company delivers over 41 billion components and devices annually, ensuring efficient production capabilities and reliable support for its customers.
See More
Eli Lilly's Dominance in Obesity Drug Market Reinforced
- Clinical Trial Comparison: Eli Lilly's Zepbound demonstrated superior efficacy in a head-to-head trial, with participants losing an average of 25.5% of their body weight compared to Novo Nordisk's CagriSema at 23%, reinforcing Lilly's leadership in obesity drug effectiveness and solidifying its market position.
- New Device Launch: Lilly introduced a new Zepbound injection device in the U.S. that provides a month's supply, enhancing patient convenience; while the immediate financial impact may be limited, it showcases Lilly's supply chain advantages and commitment to patient care.
- Significant Market Reaction: Following disappointing trial results, Novo Nordisk's shares fell over 15%, while Lilly's stock rose more than 4%, reflecting investor confidence in Lilly's growth potential and widening the gap between the two companies in the market.
- Future Development Potential: Lilly is advancing multiple next-generation obesity treatments, including retatrutide and eloralintide, targeting appetite-related hormones, with analysts noting that Lilly's competitive edge is expanding, positioning the company for further market leadership in the obesity drug sector.
See More
West Pharmaceutical Services Authorizes $1B Share Repurchase Program
- Share Repurchase Program: West Pharmaceutical Services' board has authorized a share repurchase program of up to $1 billion, indicating strong confidence in the company's value and aiming to enhance earnings per share through this initiative.
- Completion of Previous Buyback: The company has fully executed its prior buyback program, which expired on December 31, demonstrating a proactive approach to capital management and a commitment to shareholder returns.
- Optimistic Performance Outlook: West Pharmaceutical targets organic revenue growth of 5% to 7% for 2026, primarily driven by accelerating demand for high-value products (HVP), reflecting strong market demand for its offerings.
- Exceeding Market Expectations: The company reported fourth-quarter results for 2025 that surpassed market expectations, further boosting investor confidence in its future growth potential and likely attracting increased investor interest.
See More
West Pharmaceutical Declares Quarterly Dividend and Share Repurchase Program
- Quarterly Dividend Declaration: On February 16, 2026, West Pharmaceutical's Board declared a quarterly dividend of $0.22 per share, payable on May 6, 2026, to shareholders of record on April 29, 2026, reflecting the company's ongoing profitability and commitment to shareholder returns.
- Share Repurchase Program Initiation: The company authorized a new share repurchase program on February 17, 2026, allowing for the repurchase of up to $1 billion in common stock, aimed at enhancing shareholder value and boosting market confidence through flexible adjustments based on market conditions and stock price fluctuations.
- Repurchase Flexibility: This repurchase program has no expiration date, allowing the company to suspend or terminate it at any time based on market conditions, demonstrating its flexibility in capital management and ability to respond to market volatility.
- Successful Historical Repurchase: West Pharmaceutical fully utilized its previous repurchase program before its expiration on December 31, 2025, indicating a proactive approach to capital returns and effective shareholder value management.
See More
WEST PHARMACEUTICAL SERVICES INC: UBS LOWERS TARGET PRICE FROM $355 TO $340
Company Overview: West Pharmaceutical Services, Inc. is a leading provider of pharmaceutical packaging and delivery solutions.
Stock Price Adjustment: The company has cut its target stock price from $355 to $340.
See More
